A5078964682- Dermatology and Skin Diseases
- Allergic Rhinitis and Sensitization
- Asthma and respiratory diseases
- Food Allergy and Anaphylaxis Research
- Cutaneous Melanoma Detection and Management
- Autoimmune Bullous Skin Diseases
- Nail Diseases and Treatments
- Psoriasis: Treatment and Pathogenesis
- Urticaria and Related Conditions
- Nonmelanoma Skin Cancer Studies
- Hidradenitis Suppurativa and Treatments
- Colorectal and Anal Carcinomas
- Transgenic Plants and Applications
- Skin Protection and Aging
- Hair Growth and Disorders
- Adrenal Hormones and Disorders
- Pharmaceutical studies and practices
- Chemotherapy-related skin toxicity
- Microscopic Colitis
- melanin and skin pigmentation
- Cancer and Skin Lesions
- Health Systems, Economic Evaluations, Quality of Life
- Melanoma and MAPK Pathways
- Vasculitis and related conditions
- Cell Image Analysis Techniques
MemorialCare Health System
2021-2025
Skin Cancer Foundation
2017-2022
University of Central Florida
2008-2011
Florida College
2008-2011
University of Manchester
2011
Geisinger Medical Center
2007-2009
Virginia Commonwealth University Medical Center
2005-2007
University Health System
2007
University of Milan
1990
Hidradenitis suppurativa is a painful, chronic inflammatory skin disease with few options for effective treatment. In phase 2 trial, adalimumab, an antibody against tumor necrosis factor α, showed efficacy hidradenitis suppurativa.PIONEER I and II were similarly designed, 3 multicenter trials of adalimumab suppurativa, two double-blind, placebo-controlled periods. period 1, patients randomly assigned in 1:1 ratio to 40 mg weekly or matching placebo 12 weeks. 2, reassigned at every-other-week...
The oral Janus kinase 1 (JAK1) inhibitor abrocitinib, which reduces interleukin-4 and interleukin-13 signaling, is being investigated for the treatment of atopic dermatitis. Data from trials comparing JAK1 inhibitors with monoclonal antibodies, such as dupilumab, that block receptors are limited.In a phase 3, double-blind trial, we randomly assigned patients dermatitis was unresponsive to topical agents or warranted systemic therapy (in 2:2:2:1 ratio) receive 200 mg 100 abrocitinib orally...
Importance The effect of continued treatment with tirzepatide on maintaining initial weight reduction is unknown. Objective To assess the tirzepatide, diet and physical activity, maintenance reduction. Design, Setting, Participants This phase 3, randomized withdrawal clinical trial conducted at 70 sites in 4 countries a 36-week, open-label lead-in period followed by 52-week, double-blind, placebo-controlled included adults body mass index greater than or equal to 30 27 weight-related...
Significant unmet need exists for long-term treatment of moderate to severe atopic dermatitis (AD).To assess the safety and efficacy dupilumab in patients with AD.This ongoing, multicenter, open-label extension study (NCT01949311) evaluated adults who had previously participated phase 1 through 3 clinical trials AD. This analysis examined given 300 mg weekly up 76 weeks at data cutoff (April 2016). Safety was primary outcome; also evaluated.Of 1491 enrolled (1042.9 patient-years), 92.9% were...
Ruxolitinib (RUX) cream demonstrated potent anti-inflammatory and antipruritic efficacy in a phase 2 study adults with atopic dermatitis (AD).To evaluate 8-week safety 3 studies of RUX patients AD.Topical Evaluation Atopic Dermatitis Study 1 (NCT03745638) (NCT03745651) enrolled aged ≥12 years AD for ≥2 years, an Investigator's Global Assessment score 2/3, 3%-20% affected body surface area. Patients were randomized 2:2:1 to twice-daily 0.75% cream, 1.5% or vehicle 8 continuous weeks. The...
<h3>Importance</h3> Atopic dermatitis is associated with substantial patient and caregiver burden. Currently available treatments for atopic are inadequate or contraindicated some patients. Abrocitinib (PF-04965842) an oral Janus kinase 1 selective inhibitor under investigation the treatment of dermatitis. <h3>Objective</h3> To investigate efficacy safety abrocitinib patients moderate to severe <h3>Design, Setting, Participants</h3> A phase 2b, randomized, double-blinded, placebo-controlled,...
Hidradenitis suppurativa (HS) is a chronic inflammatory disease with high burden for patients and limited existing therapeutic options.To evaluate the efficacy safety of bimekizumab, monoclonal IgG1 antibody that selectively inhibits interleukin 17A 17F in individuals moderate to severe HS.This phase 2, double-blind, placebo-controlled randomized clinical trial an active reference arm was performed from September 22, 2017, February 21, 2019. The study included 2- 4-week screening period,...
The tubulin polymerization and Src kinase signaling inhibitor tirbanibulin is being investigated as a topical treatment for actinic keratosis, precursor of squamous-cell carcinoma.
Lebrikizumab (LEB), a high-affinity monoclonal antibody targeting interleukin (IL)-13, demonstrated efficacy and safety in patients with moderate-to-severe atopic dermatitis (AD) during 16 weeks of monotherapy phase 2b trial, two 52-week 3 trials.To evaluate LEB combined low- to mid-potency topical corticosteroids (TCS) AD.The ADhere trial was 16-week randomized, double-blinded, placebo (PBO)-controlled, multicenter, clinical conducted from February 3, 2020, September 16, 2021. The study at...
Background The topical phosphodiesterase 4 inhibitor roflumilast has been studied in several dermatologic conditions. Objective Roflumilast foam 0.3% is being investigated as a treatment for seborrheic dermatitis (SD). Methods In this phase 3, double-blinded trial, patients with SD were randomly assigned (2:1 ratio) to once-daily or vehicle 8 weeks. primary efficacy outcome was Investigator Global Assessment (IGA) Success at week 8, defined IGA of 0 (Clear) 1 (Almost Clear) plus ≥2-point...
Patients with psoriasis value rapid and complete skin clearance. No head‐to‐head studies have focused on early responses to interleukin (IL)‐17 vs. IL‐23 inhibitors. To compare clearance by the IL‐17A inhibitor ixekizumab IL‐23p19 guselkumab. IXORA‐R, a 24‐week, randomized, double‐blinded study, enrolled adults moderate‐to‐severe plaque [static Physician's Global Assessment of Disease (sPGA) score ≥ 3, Psoriasis Area Severity Index (PASI) 12, 10% body surface area]. were randomized (1 : 1)...
ASN002 is an oral dual inhibitor of Janus kinase and spleen tyrosine kinase, which are involved in the pathogenesis atopic dermatitis (AD) through their regulatory role on T helper (Th)1, Th2 Th17/Th22 pathways. The objectives this study were to evaluate efficacy, safety, pharmacokinetics effects systemic biomarkers patients with moderate‐to‐severe AD. Methods A total 36 AD randomized (3 : 1) or placebo phase Ib study. Three dosage cohorts studied over a 28‑day period (20 mg, 40 mg 80 once...
BackgroundThere are no treatments approved by the Food and Drug Administration for alopecia areata.ObjectiveTo evaluate efficacy safety of baricitinib in patients with ≥50% scalp hair loss a phase 2 study adults areata (BRAVE-AA1).MethodsPatients were randomized 1:1:1:1 to receive placebo or 1 mg, 4 mg once daily. Two consecutive interim analyses performed after all completed weeks 12 36 had discontinued treatment prior these time points. The primary endpoint was proportion achieving...
BackgroundHidradenitis suppurativa (HS) is a debilitating, inflammatory skin disease with limited treatment options and partially understood pathophysiology. Using an umbrella trial design, three kinase inhibitor immunomodulators different mechanisms of action were evaluated.MethodsThis phase 2a, double-blind, parallel-group enrolled adults moderate to severe HS who then randomly assigned (1:1:1:1) once-daily brepocitinib 45 mg (a JAK1/TYK2 inhibitor), zimlovisertib 400 (an IRAK4...
Importance Safe, effective, and well-tolerated topical treatment options available for long-term use in patients with atopic dermatitis (AD) are limited associated low adherence rates. Objective To evaluate efficacy safety of once-daily roflumilast cream, 0.15%, vs vehicle cream AD. Design, Setting, Participants Two phase 3, randomized, double-blind, vehicle-controlled trials (Interventional Trial Evaluating Roflumilast Cream the Treatment Atopic Dermatitis 1 2 [INTEGUMENT-1 INTEGUMENT-2]),...
Abstract Background Acne‐induced hyperpigmentation (AIH) may accompany acne vulgaris (AV) inflammation in all skin phototypes. Trifarotene has shown depigmenting properties vivo. This study evaluated trifarotene plus skincare because it is increasingly recognized that holistic AV management should include and treatments. Methods a phase IV double‐blind, parallel‐group of patients (13–35 years) with moderate AIH treated ( N = 60) or vehicle 63) regimen (moisturizer, cleanser, sunscreen) for...
Ruxolitinib cream has demonstrated anti-inflammatory and antipruritic activity was well tolerated in a phase 3 study patients aged 2–11 years with mild to moderate atopic dermatitis (AD). This examined the safety, tolerability, pharmacokinetics, efficacy, quality of life (QoL) ruxolitinib under maximum-use conditions longer-term use. Eligible were severe AD [Investigator's Global Assessment (IGA) score 3–4], ≥ 35% affected body surface area (BSA). Patients applied 1.5% twice daily all...
Current topical treatment options for seborrheic dermatitis are limited by efficacy and/or safety.To assess safety and of roflumilast foam, 0.3%, in adult patients with affecting the scalp, face, trunk.This multicenter (24 sites US Canada) phase 2a, parallel group, double-blind, vehicle-controlled clinical trial was conducted between November 12, 2019, August 21, 2020. Participants were (aged ≥18 years) a diagnosis 3-month or longer duration Investigator Global Assessment (IGA) score 3...
Summary Background Weekly adalimumab (Humira®) is approved for the treatment of hidradenitis suppurativa (HS) based on 12-week placebo-controlled periods two phase III PIONEER trials. Objectives Using integrated trial results, we aimed to evaluate optimal medium-term maintenance dosing strategy moderate-to-severe HS. Methods Each had double-blind periods; Period A and 24-week B. Patients randomized 40 mg every week (ADAew) (Period A), were rerandomized in B ADAew (ADAew/ew), ADA other...